- Home
- INMB vs IXHL Comparison
INMB vs IXHL Comparison
Compare INMB & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- IXHL
- Stock Information
- Founded
- INMB 2015
- IXHL 2001
- Country
- INMB United States
- IXHL Australia
- Employees
- INMB N/A
- IXHL N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- IXHL
- Sector
- INMB Health Care
- IXHL
- Exchange
- INMB Nasdaq
- IXHL Nasdaq
- Market Cap
- INMB 49.2M
- IXHL 49.1M
- IPO Year
- INMB 2019
- IXHL N/A
- Fundamental
- Price
- INMB $1.83
- IXHL $0.38
- Analyst Decision
- INMB Hold
- IXHL
- Analyst Count
- INMB 3
- IXHL 0
- Target Price
- INMB $4.30
- IXHL N/A
- AVG Volume (30 Days)
- INMB 361.9K
- IXHL 28.1M
- Earning Date
- INMB 10-30-2025
- IXHL 11-14-2025
- Dividend Yield
- INMB N/A
- IXHL N/A
- EPS Growth
- INMB N/A
- IXHL N/A
- EPS
- INMB N/A
- IXHL N/A
- Revenue
- INMB $50,000.00
- IXHL $86,000.00
- Revenue This Year
- INMB $264.29
- IXHL $1,188.37
- Revenue Next Year
- INMB $9,819.61
- IXHL N/A
- P/E Ratio
- INMB N/A
- IXHL N/A
- Revenue Growth
- INMB 19.05
- IXHL 616.67
- 52 Week Low
- INMB $1.71
- IXHL $0.08
- 52 Week High
- INMB $11.64
- IXHL $3.12
- Technical
- Relative Strength Index (RSI)
- INMB 44.66
- IXHL 45.03
- Support Level
- INMB $1.73
- IXHL $0.34
- Resistance Level
- INMB $1.89
- IXHL $0.41
- Average True Range (ATR)
- INMB 0.10
- IXHL 0.03
- MACD
- INMB 0.00
- IXHL 0.01
- Stochastic Oscillator
- INMB 37.04
- IXHL 47.69
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.